Drug Trial Radar · NCT07235202
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Dec 24, 2025
Primary completion
Jun 22, 2028
Study completion Dec 22, 2028
Sponsor
- Lead sponsor
- Shenzhen Majory Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed after first-line therapy.
Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
MR001Drug
Intravenous infusion
Irinotecan Liposome Injection combined with 5-FU/LVDrug
Per locally approved formulation
Nab-paclitaxelDrug
Per locally approved formulation
Gemcitabine (GEM)Drug
Per locally approved formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Approximately 12 months
- Maximum Tolerated Dose (MTD) of MR001Time frame: Approximately 12 months
- Incidence of Adverse Events (AEs) as Assessed by CTCAE v5.0Time frame: Approximately 30 months
- Objective Response Rate (ORR)Time frame: Approximately 24 months
- Best Overall Response (BOR)Time frame: Approximately 24 months
- Disease control rate (DCR)Time frame: Approximately 24 months
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Shenzhen People's Hospital
Shenzhen, Guangdong, China · Not yet recruiting
Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen
Shenzhen, Guangdong, China · Not yet recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
The Second People's Hospital of Yibin
Yibin, Sichuan, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.